LYL1 Gene - Lymphoblastic Leukemia Associated Hematopoiesis Regulator

Comprehensive genomic and functional analysis of LYL1, a basic helix-loop-helix transcription factor implicated in T-cell acute lymphoblastic leukemia and hematopoietic development.

Gene Information Card

Symbol LYL1
Full Name lymphoblastic leukemia associated 1
Gene Type protein-coding
Chromosomal Location 19p13.13
NCBI Gene ID 4066 ncbi.nlm.nih.gov/gene/4066
Ensembl ID ENSG00000104903
UniProt ID P12980
OMIM ID 151440
HGNC ID 6731
Aliases bHLHa18, TAL-1-related, TAL1R

Description

LYL1 (lymphoblastic leukemia associated 1) encodes a basic helix-loop-helix (bHLH) transcription factor that plays a critical role in hematopoiesis, particularly in the development of erythroid and megakaryocytic lineages. It is frequently dysregulated in T-cell acute lymphoblastic leukemia (T-ALL) through chromosomal translocations or aberrant expression. LYL1 forms heterodimers with E-proteins (e.g., TCF3/E2A) to regulate target gene transcription involved in cell proliferation and differentiation.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
T-cell acute lymphoblastic leukemia (T-ALL) LYL1 is activated by chromosomal translocations (e.g., t(7;19)(q35;p13)) that place it under the control of T-cell receptor enhancers, leading to aberrant expression and blockade of T-cell differentiation. PMID: 1902990; COSMIC; ClinVar
Acute myeloid leukemia (AML) Overexpression of LYL1 has been reported in AML subtypes, potentially contributing to leukemogenesis by disrupting normal hematopoietic differentiation. PMID: 10655559; COSMIC
Hematopoietic disorders Dysregulation of LYL1 expression may impair erythroid/megakaryocyte development, though direct disease associations are less defined. OMIM: 151440

Expression Profile

Tissue Expression
Tissue nTPM level
Bone marrow 12.5 Medium
Spleen 8.3 Low
Thymus 6.1 Low
Lung 2.4 Not detected
Heart 1.1 Not detected
Cell Line Expression
Cell Line nTPM Notes
K562 (erythroleukemia) 45.2 High expression; used as model for erythroid differentiation
Jurkat (T-cell leukemia) 32.8 High expression; relevant to T-ALL
HEK293 (embryonic kidney) 1.5 Low/background expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1A>G (p.Met1?) missense <0.1% Potential loss of start codon; uncertain significance
c.200C>T (p.Pro67Leu) missense <0.1% Rare variant; no functional data
t(7;19)(q35;p13) translocation rare in T-ALL Fusion with TCRB enhancer; drives LYL1 overexpression
Mutation functional classification

Loss of Function (LOF)

No confirmed loss-of-function mutations reported in disease; experimental knockdown in cell lines impairs erythroid differentiation.

Gain of Function (GOF)

Chromosomal translocations leading to overexpression in T-ALL represent a gain-of-function mechanism.

Dominant Negative (DN)

Not described for LYL1; dominant-negative effects are hypothesized for certain bHLH mutants but not validated.

Pathways

• Hematopoietic stem cell differentiation (Reactome: R-HSA-9616222)
• Transcriptional regulation by bHLH factors (KEGG: hsa04350)
• T-cell receptor signaling in T-ALL (KEGG: hsa05202)

Protein Summary

LYL1 is a 280-amino acid bHLH transcription factor that localizes to the nucleus and binds E-box DNA sequences (CANNTG) as a heterodimer with E-proteins. It is essential for primitive and definitive hematopoiesis, particularly erythroid and megakaryocyte lineage commitment. In cancer, aberrant LYL1 expression blocks T-cell differentiation, contributing to leukemogenesis. The protein contains a conserved bHLH domain (residues 109-160) required for DNA binding and dimerization.

Related Products

Product name Cat.No. Species Gene ID
LYL1 Knockout HEK293 Cell Line EDJ-KQ2530 Human 4066 Details Get a Quote
LYL1 Knockout HCT 116 Cell Line EDJ-KQ23155 Human 4066 Details Get a Quote
LYL1 Knockout HeLa Cell Line EDJ-KQ53818 Human 4066 Details Get a Quote
LYL1 Knockout A-549 Cell Line EDJ-KQ62298 Human 4066 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: